RCKT
Rocket Pharmaceuticals, Inc. · Healthcare · Biotechnology
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q2 2024
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 80 | -1 | 55.09M | $188.40M | +4 | −5 |
| Q1 2026 | 83 | +2 | 57.14M | $204.44M | +8 | −6 |
| Q4 2025 | 81 | +2 | 51.01M | $179.05M | +2 | — |
| Q3 2025 | 15 | 0 | 38.20M | $124.54M | — | — |
| Q2 2025 | 12 | -1 | 25.35M | $62.12M | +2 | −3 |
| Q1 2025 | 10 | -1 | 24.61M | $164.16M | +1 | −2 |
| Q4 2024 | 11 | 0 | 29.17M | $366.63M | +1 | −1 |
| Q3 2024 | 10 | 0 | 19.68M | $363.43M | +2 | −2 |
| Q2 2024 | 10 | — | 17.23M | $370.95M | — | — |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Wellington Management ✦ | 9.16M | — | $197.12M | 0.0% | n/c | 1 | SEC ↗ |
| 2 | Wellington Management ✦ | 9.16M | — | $197.12M | 0.0% | n/c | 1 | SEC ↗ |
| 3 | Wellington Management ✦ | 9.16M | — | $197.12M | 0.0% | n/c | 1 | SEC ↗ |
| 4 | Wellington Management ✦ | 9.16M | — | $197.12M | 0.0% | n/c | 1 | SEC ↗ |
| 5 | Wellington Management ✦ | 9.16M | — | $197.12M | 0.0% | n/c | 1 | SEC ↗ |
| 6 | Wellington Management ✦ | 9.16M | — | $197.12M | 0.0% | n/c | 1 | SEC ↗ |
| 7 | Wellington Management ✦ | 9.16M | — | $197.12M | 0.0% | n/c | 1 | SEC ↗ |
| 8 | Wellington Management ✦ | 9.16M | — | $197.12M | 0.0% | n/c | 1 | SEC ↗ |
| 9 | T. Rowe Price ✦ | 3.17M | — | $68.24M | 0.0% | n/c | 1 | SEC ↗ |
| 10 | T. Rowe Price ✦ | 3.17M | — | $68.24M | 0.0% | n/c | 1 | SEC ↗ |
| 11 | Citadel Advisors ✦ | 2.82M | — | $60.67M | 0.1% | n/c | 1 | SEC ↗ |
| 12 | Citadel Advisors ✦ | 2.82M | — | $60.67M | 0.1% | n/c | 1 | SEC ↗ |
| 13 | Geode Capital Management ✦ (passive) | 1.60M | — | $34.53M | 0.0% | n/c | 1 | SEC ↗ |
| 14 | Geode Capital Management ✦ (passive) | 1.60M | — | $34.53M | 0.0% | n/c | 1 | SEC ↗ |
| 15 | Adage Capital Partners ✦ | 200.00K | — | $4.31M | 0.0% | n/c | 1 | SEC ↗ |
| 16 | Millennium Management ✦ | 105.33K | — | $2.27M | 0.0% | n/c | 1 | SEC ↗ |
| 17 | Renaissance Technologies ✦ | 99.57K | — | $2.14M | 0.0% | n/c | 1 | SEC ↗ |
| 18 | Norges Bank ✦ (passive) | 34.75K | — | $748,211 | 0.0% | n/c | 1 | SEC ↗ |
| 19 | Two Sigma Investments ✦ | 23.09K | — | $497,149 | 0.0% | n/c | 1 | SEC ↗ |
| 20 | Marshall Wace ✦ | 19.58K | — | $421,622 | 0.0% | n/c | 1 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 195 holders, 96.37M shares, $341.40M reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer · 2.29K sh · $7,753
Officer · 631 sh · $2,133
Officer · 4.70K sh · $16,449
Officer · 36.66K sh · $128,266
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology